Abstract:Abstract The capsular polysaccharide of the human pathogen Group B Streptococcus is a key virulence factor and vaccine candidate that induces protective antibodies when conjugated to carrier proteins. It consists of long polymeric chains of oligosaccharide repeating units, and each of the ten capsular serotypes described so far presents a unique chemical structure with distinct antigenic properties; therefore, broad protection against this pathogen could be achieved by a combination of ten glycoconjugates. Capsular polysaccharide biosynthesis and assembly follow a polymerase-dependent pathway that is widespread in encapsulated bacteria and is encoded by a polycistronic operon. Here we exploited the sequence similarity between the capsule operons of types V and IX to generate hybrid polysaccharides incorporating epitopes of both serotypes in a single molecule, by co-expressing their specific CpsM, O, I glycosyltransferases in a single isolate. Physicochemical and immunochemical methods confirmed that an engineered strain produced a high molecular weight chimeric polysaccharide, combining antigenic specificities of both type V and IX. By optimizing the copy number of key glycosyltransferase genes, we were able to modulate the ratio between type-specific epitopes. Finally, vaccination with chimeric glycoconjugates significantly decreased the incidence of disease in pups born from immunized mice challenged with either serotype. This study provides proof of concept for a new generation of glycoconjugate vaccines that combine the antigenic specificity of different polysaccharide variants in a single molecule, eliciting a protective immune response against multiple serotype variants.

What problem does this paper attempt to address?

### What problems does this paper attempt to solve? This paper aims to develop a new type of multivalent vaccine candidate by constructing chimeric capsular polysaccharides (cCPS) containing the characteristic epitopes of Group B Streptococcus (GBS) serotypes V and IX in group A. GBS is an important pathogen that can cause severe infections in neonates, infants and the elderly. The capsular polysaccharide (CPS) on its surface is the main virulence factor and can induce protective antibodies when combined with carrier proteins. Specifically, the paper attempts to solve the following key problems: 1. **Achieving broad - spectrum protection**: - GBS has ten different serotypes (Ia, Ib, II to IX), and each serotype has a unique chemical structure and antigenic properties. Therefore, in order to achieve broad protection against all serotypes, theoretically, ten different glycoconjugate vaccines need to be combined. This not only increases the complexity and production cost of the vaccine but may also affect the effectiveness of the immune response. 2. **Generating chimeric polysaccharide molecules**: - The authors took advantage of the sequence similarity between the capsule operons of serotypes V and IX and introduced the epitopes of the two serotypes in a single molecule by co - expressing specific glycosyltransferases, thereby generating chimeric polysaccharides. This method can simplify vaccine design and improve the breadth of immune protection. 3. **Optimizing the antigen - specific ratio**: - By adjusting the copy number of key glycosyltransferase genes, the authors were able to regulate the ratio of different serotype - specific epitopes to optimize the immunogenicity of the chimeric polysaccharide. 4. **Verifying the effectiveness of the chimeric vaccine**: - Finally, the authors evaluated the protective effect of the chimeric glycoconjugate vaccine through a mouse model. The results showed that vaccination with the chimeric vaccine significantly reduced the risk of neonatal pups being infected with serotype V or IX GBS after maternal immunization. ### Summary of the core content of the paper - **Background**: Infections caused by GBS threaten the lives and health of neonates, infants and the elderly. Existing single - serotype vaccines cannot provide broad protection against all serotypes. - **Objective**: To develop a new type of multivalent vaccine to achieve protection against multiple serotypes through chimeric polysaccharide - conjugate vaccines. - **Methods**: - Utilize the similarity between the capsule operons of serotypes V and IX, co - express specific glycosyltransferases to generate chimeric polysaccharides. - Adjust the ratio of different serotype - specific epitopes by changing the copy number of key genes. - Use physicochemical and immunochemical methods such as NMR spectroscopy to confirm the structure and antigenic properties of the chimeric polysaccharide. - Evaluate the protective effect of the chimeric vaccine through a mouse model. - **Results**: - Successfully generated high - molecular - weight chimeric polysaccharides containing the characteristic epitopes of serotypes V and IX. - Vaccination with the chimeric vaccine significantly reduced the risk of neonatal pups being infected with serotype V or IX GBS, demonstrating the effectiveness of the chimeric vaccine. Through these studies, the authors provided a proof - of - concept for the design of a new generation of multivalent glycoconjugate vaccines and demonstrated the possibility of achieving broad - spectrum protection through chimeric polysaccharide - conjugate vaccines.

Group B Streptococcus chimeric capsular polysaccharides as novel multivalent vaccine candidates

Development and Immunogenicity of a Prototype Multivalent Group B Streptococcus Bioconjugate Vaccine

Synthesis and immunological study of tetrasaccharide repeating units of capsular polysaccharide of Group B Streptococcus serotype VIII and their protein conjugates

Using Surface Immunogenic Protein as a Carrier Protein to Elicit Protective Antibody to Multiple Serotypes for Candidate Group B Streptococcal Glycan Conjugate Vaccines

A Multidisciplinary Structural Approach to the Identification of the Haemophilus influenzae Type b Capsular Polysaccharide Protective Epitope

In silico Design of a Novel Serotype Independent Vaccine Against Streptococcus pneumoniae Based on B-cell Epitope Regions of Fibronectin Binding Protein, Choline Binding Protein D, and D-alanyl-D-alanine Carboxypeptidase

A novel chimeric vaccine containing multiple epitopes for simulating robust immune activation against Klebsiella pneumoniae

A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles

Development of an Efficacious, Semisynthetic Glycoconjugate Vaccine Candidate against Streptococcus pneumoniae Serotype 1

A platform for the recombinant production of Group A Streptococcus glycoconjugate vaccines

Structure of a protective epitope of group B Streptococcus type III capsular polysaccharide

Optimization of the Process for Preparing Bivalent Polysaccharide Conjugates to Develop Multivalent Conjugate Vaccines against Streptococcus pneumoniae or Neisseria meningitidis and Comparison with the Corresponding Licensed Vaccines in Animal Models

Peptide Mimics of the Group B Meningococcal Capsule Induce Bactericidal and Protective Antibodies after Immunization

Group B Streptococcus Capsular Polysaccharide-Cholera Toxin B Subunit Conjugate Vaccines Prepared by Different Methods for Intranasal Immunization

Surface Structures of Group B Streptococcus Important in Human Immunity

Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct: investigation of immunogenicity in mice

Chemical Synthesis of Truncated Capsular Oligosaccharide of Serotypes 6C and 6D of Streptococcus pneumoniae with Their Immunological Studies

Semisynthetic glycoconjugates as potential vaccine candidates against Haemophilus influenzae type a

A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization

Multi-Antigen Outer Membrane Vesicle Engineering to Develop Polyvalent Vaccines: The Staphylococcus aureus Case

Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus